Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab vs ustekinumab in anti-TNF–experienced Crohn's disease
2020-002674-26Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of risankizumab in Crohn's disease (2 arms), sponsored by AbbVie Inc. Primary endpoint: Clinical remission at Week 24 (non-inferiority). Started Sep 2020; status: active.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2020-002674-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002674-26.